Familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) (OMIM \#601399) is an autosomal dominant disorder characterized by quantitative and qualitative platelet defects and an increased risk of AML. FPD/AML shares phenotypic similarities with Jacobsen syndrome; platelet counts show mild to moderate reductions but are variable between individuals with the same genetic etiology of disease, and a reduction in dense granule secretion is often observed as a secondary qualitative abnormality \[[@CIT0001]\]. The major clinical complication of this disorder, however, is not the bleeding tendency experienced by some patients, but the propensity for a proportion of patients to develop myelodysplasia or leukemia \[[@CIT0002]\].

The molecular genetic cause of FPD/AML was first elucidated by linkage studies which mapped the underlying genetic defect to a region on human chromosome 21q \[[@CIT0003]\]. Contained within this region is the gene encoding the master regulator of hematopoiesis, Runt-related transcription factor 1 (*RUNX1*). Variants have been identified throughout the coding region of *RUNX1* but those clustered within the region encoding the Runt homology domain (RHD), which mediates DNA binding and heterodimerization with core binding factor beta (CBF-β) \[[@CIT0004]\], and are most likely to be detrimental \[[@CIT0005]\]. *RUNX1* mutation can result in haploinsufficiency of RUNX1, or reduced RUNX1 function as a result of a dominant-negative effect, that disrupts the formation of complexes with CBF-β, thereby disturbing the regulation of genes necessary for hematopoietic stem cell (HSC) maintenance, maturation, and differentiation \[[@CIT0006],[@CIT0007]\].

Over 40 *RUNX1* mutations associated with FPD/AML have been reported in patients to date ([Table I](#T0001){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). However, the prevalence of *RUNX1* defects is believed to be underestimated and as sequencing technologies improve an increasing number of patients are being reported \[[@CIT0008],[@CIT0009]\]. The mutations reported are predominantly missense and phenotypically platelets from patients present with dense granule secretion defects and persistence of MYH10 expression which can be used as a biomarker of genetic variation \[[@CIT0001],[@CIT0010]\]. It has been suggested that the risk of malignancy is reduced in those cases having *RUNX1* defects that cause haploinsufficiency when compared to those patients with dominant-negative *RUNX1* defects. Due to the associated predisposition to myeloid malignancy with some variants in *RUNX1*, it is critical to establish diagnosis as early as possible to aid in patient management and guidance.Table I.*RUNX1* variants reported to date in patients with an FPD/AML inherited bleeding disorder. Heterozygous *RUNX1* nucleotide changes present in patients with inherited bleeding and their predicted effects on the resulting RNA or protein are also shown. Genomic variations are numbered according to positions in the NM_001001890 transcript for *RUNX1*. The references where they were initially reported is also indicated.Genomic variationProtein effectVariation typeReferencesc.16 G\>Ap.D6NMissense\[[@CIT0009]\]c.82dup888p.A28GfsX83Insertion\[[@CIT0011]\]c.236 G\>Ap.W79XNonsense\[[@CIT0001]\]c.239 G\>Ap.R80HMissense\[[@CIT0008]\]c.247 A\>Gp.K83EMissense\[[@CIT0012]\]c.270+1G\>T Splicing\[[@CIT0001],[@CIT0009]\]c.271-1G\>T Splicing\[[@CIT0003]\]c.295 G\>Cp.D99HMissense\[[@CIT0011]\]c.319 G\>Cp.A107PMissense\[[@CIT0002]\]c.322 G\>Ap.G108SMissense\[[@CIT0009]\]c.361_368delACCGCAGCp.T121HfsX9Deletion\[[@CIT0008],[@CIT0013]\]c.386 C\>Ap.A129EMissense\[[@CIT0008],[@CIT0014]\]c.415 C\>Tp.R139XNonsense\[[@CIT0015]\]c.416 G\>Ap.R139QMissense\[[@CIT0003]\]c.426delAp.Ser145AfsX4Deletion\[[@CIT0016]\]c.427 G\>Ap.G143RMissense\[[@CIT0017]\]c.427+1G\>T Splicing\[[@CIT0001]\]c.428+3delAp.R135fsX177Splicing\[[@CIT0012]\]c.505 A\>Gp.T169AMissense\[[@CIT0009]\]c.506 C\>Gp.T169RMissense\[[@CIT0008]\]c.511 G\>Tp.D171YMissense\[[@CIT0017]\]c.512 A\>Tp.D171VMissense\[[@CIT0009]\]c.520 C\>Tp.R174XNonsense\[[@CIT0003]\]c.521 G\>Ap.R174QMissense\[[@CIT0003],[@CIT0008]\]c.529 C\>Tp.R177XNonsense\[[@CIT0003]\]c.530 G\>Ap.R177QMissense\[[@CIT0008],[@CIT0009],[@CIT0014]\]c.568 G\>Ap.G190RMissense\[[@CIT0018]\]c.654delCp.T219RfsX8Deletion\[[@CIT0019]\]c.703 C\>Tp.Q235XNonsense\[[@CIT0017]\]c.707delCp.P236LfsX48Deletion\[[@CIT0020]\]c.780 C\>Ap.Y260XNonsense\[[@CIT0012]\]c.786delAp.S263PfsX21Deletion\[[@CIT0021]\]c.877 C\>Tp.R293XNonsense\[[@CIT0011]\]c.906delGp.F303SfsX264Deletion\[[@CIT0022]\]c.918_922dupp.Q308RfsX261Insertion\[[@CIT0008],[@CIT0014]\]c.1007_1013delGCATCGGp.G336AfsX229Deletion\[[@CIT0011]\]c.1011delCp.I337MfsX230Deletion\[[@CIT0008]\]c.1082 C\>Ap.S361XNonsense\[[@CIT0023]\] Figure 1.Schematic showing the protein location of all previously published variants within *RUNX1* which are implicated in FPD/AML. The Runt-homology DNA-binding domain spanning amino acids 49 to182 and the Activation domain spanning from amino acid 243 to 371 is also displayed. Alterations are numbered according to positions in the NM_001001890 transcript for *RUNX1*.

Main findings {#S0002}
=============

*RUNX1* defects are associated with mild to moderately reduced platelet counts.*RUNX1* defects are associated with reduced responses to several platelet agonists and decreased platelet secretion.*RUNX1* missense mutations are almost exclusively located in the Runt homology DNA-binding domain.*RUNX1* defects causing haploinsufficiency are thought to be associated with a lower incidence of myeloid malignancies when compared to those patients with dominant-negative *RUNX1* defects.
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